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Abstract
Pericytes are ubiquitous perivascular cells that have recently attracted interest as potential myofibroblast
precursors. In turn, myofibroblasts are the major source of extracellular matrix components that
accumulate during tissue fibrosis. Given the worldwide burden of fibrotic disease and paucity of
therapeutic options available to halt its progression, elucidating the origins of myofibroblasts is of prime
importance. The advent of genetic strategies that permit fate-mapping of specific cell populations through
permanent and heritable expression of reporter proteins has begun to shed light on the source of the
fibrogenic myofibroblast. Here we discuss recent studies in multiple organs that highlight the central role
of pericytes in the origins of fibrosis.
Introduction
Fibrosis, the accumulation of extracellular matrix
molecules that constitute scar tissue, is a global health-
care concern. As a basic wound-healing response that
occurs in any organ undergoing iterative injury, tissue
fibrosis is a major component of the pathophysiology of
many common diseases, including cardiovascular dis-
ease, cancer and chronic diseases of the liver, lung and
kidney. This highly conserved response to repetitive
injury and inflammation ultimately results in disordered
tissue architecture and organ failure, making fibrosis a
major cause of mortality worldwide. Currently there are
no European Medicines Agency (EMEA)- or Food and
Drug Administration (FDA)-approved anti-fibrotic thera-
pies, underscoring the urgent need for potent and novel
treatments for tissue fibrosis.
The myofibroblast is generally acknowledged to be the
key cell regulating tissue fibrosis through extracellular
matrix deposition and exertion of tensile force [1].
Therefore, in order to accelerate the design of rational,
targeted, anti-fibrotic therapies, recent research has
focussed on defining the origin of scar-producing
myofibroblasts in various organs, since gaining control
of the myofibroblast progenitor cell population may
allow us to arrest or even induce reversion of fibrosis
in certain disease settings [2]. Multiple cell types have
been proposed to fulfil this myofibroblast precursor
role, including epithelial cells (via the process of
epithelial-mesenchymal transition [EMT]) [3,4], bone
marrow-derived cells including fibrocytes [5-10] and
tissue-resident cells [11,12]. EMT was initially proposed
as a major source of myofibroblasts in fibrotic disease,
but recent cell fate-mapping studies in multiple organs in
rodent models have shown that EMT does not directly
contribute to the pool of collagen-producing myofibro-
blasts during fibrogenesis in vivo [13-18]. Furthermore,
several recent studies utilising cutting-edge genetic cell-
labelling techniques have drawn attention to one
particular cell type, the pericyte, as a major myofibro-
blast progenitor in a diverse range of organ fibroses. In
this review, we discuss recent advances demonstrating
that this ubiquitous perivascular cell is a major source of
myofibroblasts and how these studies have paved the
way for a universal hypothesis linking pericytes to the
origins of fibrosis (Figure 1).
What are pericytes?
The pericyte is most simply defined morphologically: a
periendothelial cell with a rounded cell body and
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cytoplasmic processes encircling one or more endothelial
cells [19]. Given the anatomic location of pericytes, it is
perhaps unsurprising that their primary role in normal
tissue homeostasis relates to vascular development,
stabilisation and integrity [20-23]. Pericytes are a type of
mural cell, principally located in the microvasculature
(consisting of capillaries but also terminal arterioles and
postcapillary venules) and as such are present in every
organ and vascular bed [24]. A more exacting definition
states that, in healthy tissue, pericytes are embedded
within the vascular basement membrane [25]. However,
as this requires electron microscopy, most studies do not
confirm this feature, relying instead on a combination of
light microscopy and multiple molecular markers to
identify pericytes. Commonly used pericyte markers
include platelet-derived growth factor receptor beta
(PDGFRb), chondroitin sulphate proteoglycan 4 (also
known as nerve/glial antigen 2 or NG2), desmin and
alpha-smooth muscle actin (aSMA) [19]. However, care-
ful interpretation of these markers is required, as no single
marker is specific for pericytes alone; some only label a
subpopulation of pericytes and several are not constitu-
tively present throughout the lifespan of every pericyte.
Furthermore, pathological states, ongoing angiogenesis
and increased vascular basement membrane turnover
make the relationship between pericytes and the vascular
basementmembranemuch less clear cut. Therefore, in the
context of tissue fibrosis, discriminating between pericytes,
other mesenchymal perivascular cells and resident tissue
fibroblasts becomes even more challenging.
Tracing pericytes in organ fibrosis
In recent years, the rapid increase in powerful, sophis-
ticated mouse genetic tools has greatly facilitated cellular
fate-mapping in multiple biological processes, including
tissue fibrosis. The Cre/loxP system is widely used for this
purpose [26]. It employs the gene for bacterial Cre
recombinase (Cre), which is linked to a cell- or lineage-
specific promoter prior to incorporation in the genome
of a transgenic mouse. Furthermore, cell fate-mapping
experiments commonly employ inducible Cre mouse
strains, as Cre expression in these mice only occurs in the
presence (or absence) of exogenous compounds (com-
monly tetracyclines or tamoxifen), thereby allowing
both temporal and spatial control over Cre expression.
When combined with a reporter mouse strain, Cre
expression in a specific cell type in the embryo or adult
causes a permanent alteration in the genome of these
cells, resulting in reporter protein expression in the
targeted cell type and its progeny.
Skin and muscle fibrosis
The origin of profibrotic cells in skin and muscle has most
recently been explored in the elegant studies of Dulauroy
et al. [27]. They examined the role of ADAM12 (a disin-
tegrin and metalloprotease 12)-positive cells during skin
and muscle injury. ADAM12 is a membrane-anchored
metalloprotease, expressed in several human diseases with
a fibrotic component, but is also, in a fashion, restricted
during development. Initial studies by Dulauroy et al.
demonstrated that transient expression of ADAM12
identifies a distinct pro-inflammatory subset of stromal
cells that become activated following acute injury in the
skin and skeletal muscle. The authors then fate-mapped
these cells using an inducible, tetracycline transactivator-
based system. This involved the generation of triple
transgenic mice that expressed tetracycline transactivator
under control of the Adam12 locus, Cre under control of
the tetracycline transactivator and the conditional reporter
Rosa26floxSTOP-YFP locus. In these mice, yellow fluorescent
protein (YFP) labelling of the progeny of ADAM12+ cells
was temporally controlled by the administration of
doxycycline to prevent Cre expression. This allowed the
separate fate-mapping of foetal and adult ADAM12+ cells
following skin or muscle injury, induced by injection of
complete Freund’s adjuvant into ear dermis or cardiotoxin
into tibialis anterior muscle respectively. The genetic
strategies employed by the authors, combined with a
parabiosis experiment utilising a transgenicmouse sutured
to a wildtype mouse, allowed them to demonstrate that
the majority of collagen-producing, aSMA+ myofibro-
blasts developing following acute dermal or muscle injury
are generated from tissue-resident ADAM12+ cells. Further-
more, ablation of ADAM12+ cells in skeletalmuscle (using
mice that also expressed the human diphtheria toxin
receptor under control of the Adam12 locus) markedly
reduced the generation of profibrotic cells and interstitial
collagen accumulation.
Figure 1. Pericytes are a major source of myofibroblasts during
fibrosis in multiple organs
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The progeny of foetal ADAM12+ cells includes a sub-
population of PDGFRb+ NG2+ perivascular cells, in
addition to nerve and glial cells. Usingmice that expressed
Cre under control of theWnt1 promoter, crossed to a YFP
reporter mouse, the authors found no contribution from
the progeny of Wnt1+ nerve and Schwann cells to the
stromal cell population following skeletal muscle injury.
They therefore concluded that the ADAM12+ profibrotic
progenitors developing in injured skeletal muscle do not
originate from a neural crest cell lineage and ADAM12+
Schwann cells, but from ADAM12+ perivascular cells. In
addition, ADAM12 itself was identified as a potential
antifibrotic target, since its silencing with siRNA reduced
collagen deposition and upregulated regenerative growth
factors following muscle injury. Overall, the findings of
Dulauroy et al. provide strong evidence that pericytes are a
major contributor to the myofibroblast population that
develops during skin and muscle scarring.
Kidney fibrosis
Pericytes in the kidney have also been intensively studied
in order to analyse their contribution to renal myofibro-
blast formation and fibrosis. Almost a decade ago,
Faulkner et al. reported that the myofibroblast popula-
tion in a Habu venom and angiotensin II model of renal
fibrosis appeared to expand from a perivascular location
[28]. This observation was subsequently supported by
Lin et al. using a Col-green fluorescent protein (GFP)
mouse, which expresses the GFP reporter under control
of the collagen-a1(I) promoter/enhancer, and subse-
quently co-staining for commonly used pericyte markers
including NG2, PDGFRb and aSMA [29]. This allowed
them to identify pericytes and perivascular fibroblasts in
the uninjured kidney and their expansion into an
interstitial myofibroblast population following induc-
tion of renal fibrosis.
However, it is only lately that the appropriate genetic
tools have permitted true fate-mapping of renal myo-
fibroblast precursors during renal fibrogenesis.
Humphreys et al. utilised a Cre reporter strategy to label
renal epithelial cells or renal stromal cells in mice
permanently and heritably [15]. Renal stromal cells,
which include mesangial cells, vascular smooth muscle
cells and pericytes, were labelled using a FoxD1-Cre driver
bred into the ROSA26 reporter mouse, leading to LacZ
expression in the stromal cell population. FoxD1 is a
transcription factor expressed in metanephric mesench-
yme during kidney development. Because FoxD1 can also
be expressed in the adult kidney, a transgenic mouse in
which Cre expression by FoxD1+ cells was inducible
(through tamoxifen administration) and could therefore
be limited to embryonic development was also utilised.
Prior to injury, LacZ-expressing stromal cells in the adult
kidney interstitium co-expressed the pericyte / perivascu-
lar fibroblast markers PDGFRb and CD73. Following
unilateral ureteric obstruction to induce renal fibrosis,
there was marked expansion of the LacZ-expressing cell
population and these cells made up almost the entire
population of aSMA+ myofibroblasts. No epithelial cells
contributed to the interstitial myofibroblast population
when renal fibrosis was induced in the mice in which
renal epithelial cells were heritably labelled. Therefore,
the results obtained, using both the unilateral ureteric
obstruction model and also an ischaemia-reperfusion
model, provide strong evidence that renal myofibroblasts
almost exclusively derive from stromal precursors and not
through EMT of renal epithelial cells. Furthermore, co-
localisation of the inherited marker with PDGFRb and
CD73 suggests that these precursor cells are pericytes or
perivascular fibroblasts.
Fibrosis in the central nervous system
Many studies investigating scar formation in the central
nervous system (CNS) have focussed on the role of
astrocytes and indeed reference is often made to the ‘glial
scar’ [30]. However, in a recent study, Göritz et al.
switched focus to the stromal, non-glial core of the CNS
scar [31]. Using tamoxifen-inducible Glast-CreER mice
crossed with a YFP reporter, the authors labelled a
subpopulation of pericytes lining blood vessels in the
spinal cord parenchyma prior to spinal cord injury. These
labelled cells, referred to as Type A pericytes, expressed
PDGFRa and PDGFRb and electron microscopy con-
firmed a perivascular location surrounded by basal
lamina. Following spinal cord injury by dorsal funiculus
incision or dorsal hemisection, the number of labelled
cells increased and formed the core of the scar in the
spinal cord. These cells also began to express fibronectin
and (transiently) aSMA which, combined with ultra-
structural examination, led the authors to conclude they
were the main source of connective tissue in the scar.
Furthermore, the authors devised an elegant genetic
strategy to prevent the Type A pericyte population
expanding following spinal cord injury. They generated
multi-transgenic mice that, in addition to carrying the
Glast-CreER and YFP reporter alleles, were homozygous
for H-ras and N-ras null alleles and for floxed K-ras
alleles. As ras genes are necessary for cell cycle progres-
sion and mitosis, this allowed the investigators to inhibit
mitosis in Type A pericytes in a temporal fashion through
tamoxifen induction of Cre expression. Following spinal
cord injury, these mice had a markedly reduced stromal
cell core within the scar, with some of the mice even
manifesting an open tissue defect, demonstrating that
type A pericytes in the CNS are required for sealing spinal
cord lesions.
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Notwithstanding the detailed ultrastructural analysis
undertaken by the authors, the use of Glast-CreER to
target pericytes has been questioned, as it may also be
expressed in other CNS cell types [32]. However, it is
clear that these PDGFRb+ Glast+ perivascular cells are of
prime importance in scar formation following spinal
cord injury.
Liver fibrosis
Hepatic stellate cells (HSCs) are liver-specific pericytes that
reside in the space ofDisse in close contact with sinusoidal
endothelial cells [33,34]. Over one hundred years after
their first description, a major advance in the under-
standing of HSC function occurred with the discovery that
HSCs are the principal collagen-producing cells in the liver
[35,36]. These seminal studies, which involved ex vivo
culture of hepatic cell populations, stimulated the genesis
of the now classical paradigm of HSCs undergoing
activation to a proliferative, contractile, matrix-secreting,
myofibroblast phenotype following liver injury.
Recent work by Kisseleva et al. in a study primarily
designed to explore the fate of hepatic myofibroblasts
during liver fibrosis regression, reported that HSCs are
the major source of myofibroblasts in a murine model of
liver fibrosis [37]. Following carbon tetrachloride
(CCl4)-induced liver injury in Col-GFP mice, flow
cytometry was performed on isolated non-parenchymal
liver cells and GFP+ cells were considered to be
myofibroblasts. In addition, autofluorescence was used
to detect vitamin A expression, since HSCs produce and
store vitamin A. Ninety-two percent of GFP+ cells co-
expressed vitamin A and the authors concluded that
HSCs are the major source of myofibroblasts in CCl4-
induced liver injury. The observed expression of GFP
(driven by the collagen promoter) concurrent with
vitamin A autofluoresence is somewhat surprising, as it
has previously been reported that quiescent, non-
myofibroblastic HSCs are vitamin A rich (and hence
autofluorescent), but subsequently lose vitamin A upon
activation to a myofibroblast phenotype [38]. Further-
more, this was not a fate-mapping experiment in the
truest sense, since a defined cell population was not
heritably labelled. Therefore, although this study is
strongly supportive of liver pericytes (HSCs) constituting
a major source of collagen-producing myofibroblasts
following CCl4-induced liver injury, definitive fate-
mapping of HSCs demonstrating their contribution to
the hepatic myofibroblast pool in vivo has yet to be
undertaken.
Lung fibrosis
A continuing challenge in the field of pericyte biology
is the accurate identification and use of appropriate
nomenclature relating to pericytes / pericyte-like cells /
perivascular cells and their distinction from tissue fibro-
blasts, particularly in highly vascular tissues. This issue is
exemplified in the recent work by Rock et al. examining the
contribution of various cell types to pulmonary fibrosis
[18]. The authors observed abundant NG2+ PDGFRb+
desmin+ interstitial cells intimately associated with
pulmonary capillaries, but classified these cells as
‘pericyte-like’ as they did not have supplementary electron
microscopy data. The number of cells expressing these
markers increased in bleomycin-induced pulmonary
fibrosis.
The authors then utilised an inducible NG2-CreER
transgenic mouse crossed to a fluorescent reporter in a
fate-mapping study. Tamoxifen administration per-
mitted Cre expression in NG2+ cells, resulting in
expression of GFP. However, as the authors note, this
strategy was unfortunately inefficient at driving recombi-
nation, since it labelled only around 14% of NG2+ cells.
They found that these labelled cells do proliferate during
bleomycin-induced pulmonary fibrosis and continue to
express NG2 and PDGFRb. However, most of these cells
do not express what the authors refer to as ‘high levels’ of
aSMA, suggesting that they may not be myofibroblasts.
As the authors highlight, aSMA expression is dynamic
during the course of pulmonary fibrosis, so assessing
expression at a single time point has inherent limitations.
In addition, assessment of type I collagen expression as
an adjunctive myofibroblast marker may have been
useful to interrogate the NG2+ cell population further.
The authors suggest their observation that NG2+
PDGFRb+ pericyte-like cells proliferate during a murine
model of pulmonary fibrosis but do not become aSMA+
myofibroblasts may be due to organ-specific differences
in fibrotic responses or because another pericyte (-like)
subpopulation, distinct from the NG2+ subpopulation
labelled in this study, may be the source of aSMA+
myofibroblasts in the lung. Indeed, replicating cells were
detected by bromodeoxyuridine (BrdU) staining that
were not lineage-labelled and probably represented
additional stromal subpopulations proliferating in
response to fibrogenic stimuli. This possibility could be
explored further using alternative inducible transgenic
systems to label a larger percentage of the lung pericyte
population, including that which is NG2−, and thus
further define the role of pericytes in pulmonary fibrosis.
Future directions
The wealth of data generated in recent years implicating
pericytes as a major source of myofibroblasts in multiple
models of organ fibrosis has drawn attention to the
pericyte as a prime target for new anti-fibrotic therapies.
In addition, this rapidly evolving field has generated
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a number of important questions. Are there common,
basic pathways operating in pericytes across different
tissues during their transition to myofibroblasts follow-
ing injury that will allow a “one size fits all” drug
targeting approach? Or will we find that pericyte
populations in different fibrosing organs exhibit mark-
edly different biological behaviour, requiring a diverse
approach to the development of potent pharmacologic
inhibitors? Clearly, the more information we can accrue
regarding pericyte biology across the full range of organ
fibroses, the more able we shall be to inform and
accelerate the acquisition of potent, new treatments for a
wide range of fibrotic diseases. An area that warrants a
great deal more attention is the careful investigation and
phenotyping of pericyte subpopulations within a fibros-
ing organ, with the aim of identifying the most pro-
fibrogenic subpopulations and the mechanisms under-
lying the acquisition of this phenotype, both of which
will allow further refinement of drug targeting.
There is a more fundamental question that has gained
credence as pericytes have taken centre stage in the field
of fibrosis: what differentiates a pericyte from a resident
tissue fibroblast? This is particularly salient when the
pathological changes that occur during fibrosis lead to
turnover of the vascular basement membrane and
migration of the pericyte away from its perivascular
location. The margins separating these two cell popula-
tions are increasingly unclear and, in the absence of
unique markers for each cell type, this is an area that
requires further clarification. The generation of panels of
markers that could definitively identify the various
pericyte subpopulations and tissue fibroblasts within
different organs would be of great benefit. Furthermore,
although it appears attractive to target pericytes to treat
fibrosis, we cannot neglect their vital roles in normal
tissue homeostasis which, if significantly perturbed, may
exacerbate tissue dysfunction in a fibrotic organ with
already limited reserve. To this end, and in an era where
we strive towards translational medicine, further efforts
to phenotype pericytes carefully, both in healthy human
tissue and fibrotic organs, are a pre-requisite for the
successful translation of this burgeoning field into potent
new anti-fibrotic therapies.
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